KROS - Keros Therapeutics

-

$undefined

N/A

(N/A)

Keros Therapeutics NasdaqGM:KROS Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Location: 1050 Waltham Street, Lexington, MA, 02421, United States | Website: https://www.kerostx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-130.7M

Cash

720.5M

Avg Qtr Burn

N/A

Short % of Float

18.72%

Insider Ownership

2.27%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KER-012 (cibotercept) Details
Pulmonary hypertension, Cardiovascular disease

Susp. Mover™

Phase 2

Data readout

KER-050 (elritercept) Details
Blood disorder, Cancer, Myelodysplastic syndrome

Phase 2

Update

KER-050 (elritercept) Details
Blood cancer, Cystic fibrosis, Lung disease, Myelofibrosis, Cancer

Phase 2

Update

KER-065 Details
Duchenne muscular dystrophy, Neuromuscular disease

Phase 2

Initiation

Phase 1

Update

KER-047 (ALK2 inhibitor) Details
Myelodysplastic syndrome, Myelofibrosis

Failed

Discontinued

KER-047 (ALK2 inhibitor) Details
Fibrodysplasia ossificans progressiva, Anemia

Failed

Discontinued